{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"0.41","value":"0.11"},{"groupId":"OG001","lowerLimit":"0.64","upperLimit":"1.69","value":"1.07"},{"groupId":"OG002","lowerLimit":"0.59","upperLimit":"1.62","value":"1.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1744"},{"groupId":"OG001","value":"1682"},{"groupId":"OG002","value":"1673"}],"units":"Participants"}],"description":"Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.","id":"OG000","title":"Observation Arm"},{"description":"Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.","id":"OG001","title":"Herceptin 1-Year Arm"},{"description":"Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.","id":"OG002","title":"Herceptin 2-Year Arm"}],"paramType":"NUMBER","populationDescription":"Safety Population: All participants randomized/enrolled in the study according to actual treatment received. Hence, participants assigned to Herceptin who received no study treatment were analyzed in the Observation Arm.","reportingStatus":"POSTED","timeFrame":"From Baseline until time of event (maximum up to 10 years)","title":"Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}